Trial Profile
Front-Line Combination Therapy of Sunitinib Malate Plus Chemotherapy With Leucovorin/5-Fluorouracil and Irinotecan (FOLFIRI) for Rectal Cancer Patients With Synchronous Non-Resectable Metastases: A Phase II Non Controlled Study (SUREMETS).
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 01 Sep 2022
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary) ; Fluorouracil; Folinic acid; Irinotecan
- Indications Adenocarcinoma; Cancer metastases; Rectal cancer
- Focus Therapeutic Use
- Acronyms SUREMETS
- 27 Aug 2022 Status changed from withdrawn prior to enrolment to discontinued.
- 20 Jul 2009 New trial record